Taken together, our results demonstrated that both WT GXYLT1 and GXYLT1S212* enhance CRC metastasis via the MAPK pathway by interacting with ERK, and GXYLT1S212* had stronger promoting effects compared with WT GXYLT1. This evidence concerns the gene MAPK1 and colorectal carcinoma.